Recent advances in the development of immunostimulatory oligonucleotides

Current Opinion in Drug Discovery and Development

Volumn 6, Issue 2, 2003, Pages 204-217

  Uhlmann, Eugen ^a   Vollmer, Joerg ^a  

^a PFIZER INC   (United States)

Author keywords

Adjuvant; CpG motif; Immune stimulation; Oligonucleotide; Phosphorothioates; Plasmacytoid dendritic cell; Th1; Toll like receptor 9

Indexed keywords

ALPHA INTERFERON; B7 ANTIGEN; CD86 ANTIGEN; CPG 7909; CYCLOOXYGENASE 2; GAMMA INTERFERON; HEAT SHOCK PROTEIN 90; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOSTIMULATING AGENT; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; INTERLEUKIN 8; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MITOGEN ACTIVATED PROTEIN KINASE; MONOCLONAL ANTIBODY; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE SYNTHASE; OLIGODEOXYNUCLEOTIDE; PROSTAGLANDIN E2; STRESS ACTIVATED PROTEIN KINASE; TOLL LIKE RECEPTOR 9; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; TUMOR VACCINE; UNCLASSIFIED DRUG;

ALLERGIC DISEASE; ASTHMA; B CELL LYMPHOMA; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CELL TYPE; CHEMICAL MODIFICATION; CLINICAL TRIAL; CPG ISLAND; CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG MECHANISM; ENDOSOME; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSTIMULATION; INFECTION; MELANOMA; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NONHUMAN; REVIEW; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CPG ISLANDS; DNA; DNA-BINDING PROTEINS; HETEROCYCLIC COMPOUNDS; HUMANS; IMMUNITY, CELLULAR; INFECTION; OLIGONUCLEOTIDES; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 9;

EID: 0037346499     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (146)

1. Tokunaga T, Yamamoto H, Shimada S, Abe H, Fukuda T, Fujisawa Y, Furutani Y, Yano O, Kataoka T, Sudo T et al: Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. J Natl Cancer Inst (1984) 72:955-962.
2. Yamamoto S, Yamamoto T, Shimada S, Kuramoto E, Yano O, Kataoka T, Tokunaga T: DNA from bacteria, but not from vertebrates, induces interferons, activates natural killer cells and inhibits tumor growth. Microbiol Immunol (1992) 36:983-997.
3. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, Klinman DM: CpG motifs in bacterial DNA trigger direct B-cell activation. Nature (1995) 374:546-549. First paper describing the rationale for the immunostimulatory activity of unmethylated CpG ODNs.
4. Krieg AM: Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. Biochim Biophys Acta (1999) 1489:107-116.
5. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K et al: A Toll-like receptor recognizes bacterial DNA. Nature (2000) 408:740-745. This publication demonstrates, by means of TLR9 knockout experiments, that TLR9 is required for CpG-mediated immune activation.
6. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, Akira S: Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol (2002) 3:196-200.
7. Jurk M, Heil F, Vollmer J, Schetter C, Krieg AM, Wagner H, Lipford G, Bauer S: Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol (2002) 3:499.
8. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA: Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature (2001) 413:732-738.
9. Poltorak A, He X, Smirnova I, Liu MY, Huffel CV, Du X, Birdwell D, Alejos E, Silva M, Galanos C et al: Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science (1998) 282:2085-2088.
10. Bird AP: CpG islands as gene markers in the vertebrate nucleus. Trends Genet (1987) 3:342-347.
11. Chu W, Gong X, Li Z, Takabayashi K, Ouyang H, Chen Y, Lois A, Chen DJ, Li GC, Karin M et al: DNA-PKcs is required for activation of innate immunity by immunostimulatory DNA. Cell (2000) 103:909-918.
12. Ishii KJ, Takeshita F, Gursel I, Gursel M, Conover J, Nussenzweig A, Klinman DM: Potential role of phosphatidylinositol 3 kinase, rather than DNA-dependent protein kinase, in CpG DNA-induced immune activation. J Exp Med (2002) 196:269-274.
13. Chuang TH, Lee J, Kline L, Mathison JC, Ulevitch RJ: Toll-like receptor 9 mediates CpG-DNA signaling. J Leukocyte Biol (2002) 71:538-544.
14. Takeshita F, Leifer CA, Gursel I, Ishii KJ, Takeshita S, Gursel M, Klinman DM: Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol (2001) 167:3555-3558.
15. Bauer S, Kirschning CJ, Hacker H, Redecke V, Hausmann S, Akira S, Wagner H, Lipford GB: Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA (2001) 98:9237-9242. This publication demonstrates that human and murine TLR9 differ by their recognition of specific CpG sequence motifs.
16. Hartmann G, Krieg AM: Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J Immunol (2000) 164:944-953. Class B (or K) ODNs are described.
17. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, Endres S, Hartmann G: Quantitative expression of toll-like receptor 1.10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol (2002) 168:4531-4537.
18. Kadowaki N, Ho S, Antonenko S, Malefyt RW, Kastelein RA, Bazan F, Liu YJ: Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med (2001) 194:863-869.
19. Krug A, Towarowski A, Britsch S, Rothenfusser S, Hornung V, Bals R, Giese T, Engelmann H, Endres S, Krieg AM et al: Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol (2001) 31:3026-3037.
20. Zarember KA, Godowski PJ: Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol (2002) 168:554-561.
21. Bauer M, Redecke V, Eliwart JW, Scherer B, Kremer JP, Wagner H, Lipford GB: Bacterial CpG-DNA triggers activation and maturation of human CD11c-, CD123+ dendritic cells. J Immunol (2001) 166:5000-5007.
22. Jarrossay D, Napolitani G, Colonna M, Sallusto F, Lanzavecchia A: Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol (2001) 31:3388-3393.
23. Klinman DM, Takeshita F, Gursel I, Leifer C, Ishii KJ, Verthelyi D, Gursel M: CpG DNA: Recognition by and activation of monocytes. Microbes Infect (2002) 4:897-901.
24. Sparwasser T, Koch ES, Vabulas RM, Heeg K, Lipford GB, Ellwart JW, Wagner H: Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur J Immunol (1998) 28:2045-2054.
25. Stacey KJ, Sweet MJ, Hume DA: Macrophages ingest and are activated by bacterial DNA. J Immunol (1996) 157:2116-2122.
26. Cho HJ, Hayashi T, Datta SK, Takabayashi K, Van Uden JH, Horner A, Corr M, Raz E: IFN-αβ promote priming of antigen-specific CD8+ and CD4+ T lymphocytes by immunostimulatory DNA-based vaccines. J Immunol (2002) 168:4907-4913.
27. Dalpke AH, Schafer MK, Frey M, Zimmermann S, Tebbe J, Weihe E, Heeg K: Immunostimulatory CpG-DNA activates murine microglia. J Immunol (2002) 168:4854-4863.
28. Lipford GB, Bendigs S, Heeg K, Wagner H: Poly-guanosine motifs costimulate antigen-reactive CD8 T cells while bacterial CpG-DNA affect T-cell activation via antigen-presenting cell-derived cytokines. Immunology (2000) 101:46-52.
29. Rothenfusser S, Hornung V, Krug A, Towarowski A, Krieg AM, Endres S, Hartmann G: Distinct CpG oligonucleotide sequences activate human γδ T cells via interferon-α/β. Eur J Immunol (2001) 31:3525-3534.
30. Ahmad-Nejad P, Hacker H, Rutz M, Bauer S, Vabulas RM, Wagner H: Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur J Immunol (2002) 32:1958-1968. This publication provides evidence for the intracellular co-localization of CpG ODNs and TLR9 in endosomal compartments.
31. Hacker H, Mischak H, Miethke T, Liptay S, Schmid R, Sparwasser T, Heeg K, Lipford GB, Wagner H: CpG-DNA-specific activation of antigen-presenting cells requires stress kinase activity and is preceded by non-specific endocytosis and endosomal maturation. EMBO J (1998) 17:6230-6240.
32. Yi AK, Tuetken R, Redford T, Waldschmidt M, Kirsch J, Krieg AM: CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. J Immunol (1998) 160:4755-4761.
33. Manzel L, Macfarlane DE: Lack of immune stimulation by immobilized CpG-oligodeoxynucleotide. Antisense Nucleic Acid Drug Dev (1999) 9:459-464.
34. Dalpke AH, Zimmermann S, Albrecht I, Heeg K: Phosphodiester CpG oligonucleotides as adjuvants: Polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo. Immunology (2002) 106:102-112.
35. Lee SW, Song MK, Baek KH, Park Y, Kim JK, Lee CH, Cheong HK, Cheong C, Sung YC: Effects of a hexameric deoxyriboguanosine run conjugation into CpG oligodeoxynucleotides on their immunostimulatory potentials. J Immunol (2000) 165:3631-3639.
36. Liang H, Nishioka Y, Reich CF, Pisetsky DS, Lipsky PE: Activation of human B cells by phosphorothioate oligodeoxynucleotides. J Clin Invest (1996) 98:1119-1129.
37. Liang H, Reich CF, Pisetsky DS, Lipsky PE: The role of surface Ig binding in the activation of human B cells by phosphorothioate oligodeoxynucleotides. Scand J Immunol (2001) 54:551-563.
38. Peiser L, Mukhopadhyay S, Gordon S: Scavenger receptors in innate immunity. Curr Opin Immunol (2002) 14:123-128.
39. Zhu FG, Reich CF, Pisetsky DS: The role of the macrophage scavenger receptor in immune stimulation by bacterial DNA and synthetic oligonucleotides. Immunology (2001) 103:226-234.
40. An H, Xu H, Yu Y, Zhang M, Qi R, Yan X, Liu S, Wang W, Guo Z, Qin Z et al: Up-regulation of TLR9 gene expression by LPS in mouse macrophages via activation of NF-κB, ERK and p38 MAPK signal pathways. Immunol Lett (2002) 81:165-169.
41. Sweet MJ, Campbell CC, Sester DP, Xu D, McDonald RC, Stacey KJ, Hume DA, Liew FY: Colony-stimulating factor-1 suppresses responses to CpG DNA and expression of toll-like receptor 9 but enhances responses to lipopolysaccharide in murine macrophages. J Immunol (2002) 168:392-399.
42. Jung J, Yi AK, Zhang X, Choe J, Li L, Choi YS: Distinct response of human B cell subpopulations in recognition of an innate immune signal, CpG DNA. J Immunol (2002) 169:2368-2373.
43. Bohle B, Orel L, Kraft D, Ebner C: Oligodeoxynucleotides containing CpG motifs induce low levels of TNF-α in human B lymphocytes: Possible adjuvants for Th1 responses. J Immunol (2001) 166:3743-3748.
44. Pichyangkul S, Yongvanitchit K, Kum-arb U, Krieg AM, Heppner DG, Walsh DS: Whole blood cultures to assess the immunostimulatory activities of CpG oligodeoxynucleotides. J Immunol Methods (2001) 247:83-94.
45. Redford TW, Yi AK, Ward CT, Krieg AM: Cyclosporin A enhances IL-12 production by CpG motifs in bacterial DNA and synthetic oligodeoxynucleotides. J Immunol (1998) 161:3930-3935.
46. Jahrsdorfer B, Hartmann G, Racila E, Jackson W, Muhlenhoff L, Meinhardt G, Endres S, Link BK, Krieg AM, Weiner GJ: CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukocyte Biol (2001) 69:81-88.
47. Warren TL, Weiner GJ: Synergism between cytosine-guanine oligodeoxynucleotides and monoclonal antibody in the treatment of lymphoma. Semin Oncol (2002) 29:93-97.
48. Gursel M, Verthelyi D, Klinman DM: CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells. Eur J Immunol (2002) 32:2617-2622.
49. Ghosh DK, Misukonis MA, Reich C, Pisetsky DS, Weinberg JB: Host response to infection: The role of CpG DNA in induction of cyclooxygenase 2 and nitric oxide synthase 2 in murine macrophages. Infect Immun (2001) 69:7703-7710.
50. Chen Y, Zhang J, Moore SA, Ballas ZK, Portanova JP, Krieg AM, Berg DJ: CpG DNA induces cyclooxygenase-2 expression and prostaglandin production. Int Immunol (2001) 13:1013-1020.
51. Yi AK, Yoon JG, Yeo SJ, Hong SC, English BK, Krieg AM: Role of mitogen-activated protein kinases in CpG DNA-mediated IL-10 and IL-12 production: Central role of extracellular signal-regulated kinase in the negative feedback loop of the CpG DNA-mediated Th1 response. J Immunol (2002) 168:4711-4720.
52. Kitagaki K, Jain VV, Businga TR, Hussain I, Kline JN: Immunomodulatory effects of CpG oligodeoxynucleotides on established Th2 responses. Clin Diagn Lab Immunol (2002) 9:1260-1269.
53. Vicari AP, Chiodoni C, Vaure C, Ait-Yahia S, Dercamp C, Matsos F, Reynard O, Taverne C, Merle P, Colombo MP et al: Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med (2002) 196:541-549.
54. Cella M, Jarrossay D, Facchetti F, Alebardi O, Nakajima H, Lanzavecchia A, Colonna M: Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med (1999) 5:919-923.
55. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, Antonenko S, Liu YJ: The nature of the principal type 1 interferon-producing cells in human blood. Science (1999) 284:1835-1837.
56. Kadowaki N, Antonenko S, Liu YJ: Distinct CpG DNA and polyinosinic-polycytidylic acid double-stranded RNA, respectively, stimulate CD11c- type 2 dendritic cell precursors and CD11c+ dendritic cells to produce type I IFN. J Immunol (2001) 166:2291-2295.
57. Teig N, Moses D, Gieseler S, Schauer U: Age-related changes in human blood dendritic cell subpopulations. Scand J Immunol (2002) 55:453-457.
58. Ban E, Dupre L, Hermann E, Rohn W, Vendeville C, Quatannens B, Ricciardi-Castagnoli P, Capron A, Riveau G: CpG motifs induce Langerhans cell migration in vivo. Int Immunol (2000) 12:737-745.
59. Edwards AD, Manickasingham SP, Sporri R, Diebold SS, Schulz O, Sher A, Kaisho T, Akira S, Reis E Sousa C: Microbial recognition via Toll-like receptor-dependent and -independent pathways determines the cytokine response of murine dendritic cell subsets to CD40 triggering. J Immunol (2002) 169:3652-3660.
60. Schulz O, Edwards AD, Schito M, Aliberti J, Manickasingham S, Sher A, Reis E Sousa C: CD40 triggering of heterodimeric IL-12 p70 production by dendritic cells in vivo requires a microbial priming signal. Immunity (2000) 13:453-462.
61. Jakob T, Walker PS, Krieg AM, Udey MC, Vogel JC: Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: A role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. J Immunol(1998) 161:3042-3049.
62. Martin P, Del Hoyo GM, Anjuere F, Arias CF, Vargas HH, Fernandez L, Parrillas V, Ardavin C: Characterization of a new subpopulation of mouse CD8α+ B220+ dendritic cells endowed with type 1 interferon production capacity and tolerogenic potential. Blood (2002) 100:383-390.
63. Nakano H, Yanagita M, Gunn MD: CD11c+B220+Gr-1+ cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J Exp Med (2001) 194:1171-1178.
64. Neufert C, Pai RK, Noss EH, Berger M, Boom WH, Harding CV: Mycobacterium tuberculosis 19-kDa lipoprotein promotes neutrophil activation. J Immunol (2001) 167:1542-1549.
65. Bylund J, Samuelsson M, Tarkowski A, Karlsson A, Collins LV: Immunostimulatory DNA induces degranulation and NADPH-oxidase activation in human neutrophils while concomitantly inhibiting chemotaxis and phagocytosis. Eur J Immunol (2002) 32:2847-2856.
66. Krieg AM: CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol (2002) 20:709-760. An excellent and comprehensive review on all aspects of CpG ODNs.
67. Weighardt H, Feterowski C, Veit M, Rump M, Wagner H, Holzmann B: Increased resistance against acute polymicrobial sepsis in mice challenged with immunostimulatory CpG oligodeoxynucleotides is related to an enhanced innate effector cell response. J Immunol (2000) 165:4537-4543.
68. Schluesener HJ, Seid K, Deininger M, Schwab J: Transient in vivo activation of rat brain macrophages/microglial cells and astrocytes by immunostimulatory multiple CpG oligonucleotides. J Neuroimmunol (2001) 113:89-94.
69. Takeshita S, Takeshita F, Haddad DE, Janabi N, Klinman DM: Activation of microglia and astrocytes by CpG oligodeoxynucleotides. Neuroreport (2001) 12:3029-3032.
70. Stoll G, Jander S: The role of microglia and macrophages in the pathophysiology of the CNS. Prog Neurobiol (1999) 58:233-247.
71. Bsibsi M, Ravid R, Gveric D, van Noort JM: Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol (2002) 61:1013-1021.
72. Takami M, Kim N, Rho J, Choi Y: Stimulation by toll-like receptors inhibits osteoclast differentiation. J Immunol (2002) 169:1516-1523.
73. Hacker H, Vabulas RM, Takeuchi O, Hoshino K, Akira S, Wagner H: Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J Exp Med (2000) 192:595-600.
74. Schnare M, Holt AC, Takeda K, Akira S, Medzhitov R: Recognition of CpG DNA is mediated by signaling pathways dependent on the adaptor protein MyD88. Curr Biol (2000) 10:1139-1142.
75. Muzio M, Natoli G, Saccani S, Levrero M, Mantovani A: The human toll signaling pathway: Divergence of nuclear factor κB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6). J Exp Med (1998) 187:2097-2101.
76. Muzio M, Ni J, Feng P, Dixit VM: IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science (1997) 278:1612-1615.
77. Kobayashi K, Hernandez LD, Galan JE, Janeway CA Jr, Medzhitov R, Flavell RA: IRAK-M is a negative regulator of Toll-like receptor signaling. Cell (2002) 110:191-202.
78. Zhu FG, Pisetsky DS: Role of the heat shock protein 90 in immune response stimulation by bacterial DNA and synthetic oligonucleotides. Infect Immun (2001) 69:5546-5552.
79. Dalpke AH, Opper S, Zimmermann S, Heeg K: Suppressors of cytokine signaling (SOCS)-1 and SOCS-3 are induced by CpG-DNA and modulate cytokine responses in APCs. J Immunol (2001) 166:7082-7089.
80. Hacker H, Mischak H, Hacker G, Eser S, Prenzel N, Ullrich A, Wagner H: Cell type-specific activation of mitogen-activated protein kinases by CpG-DNA controls interleukin-12 release from antigen-presenting cells. EMBO J (1999) 18:6973-6982.
81. Yi AK, Yoon JG, Hong SC, Redford TW, Krieg AM: Lipopolysaccharide and CpG DNA synergize for tumor necrosis factor-α production through activation of NF-κB. Int Immunol (2001) 13:1391-1404.
82. Gao JJ, Xue Q, Papasian CJ, Morrison DC: Bacterial DNA and lipopolysaccharide induce synergistic production of TNF-α through a post-transcriptional mechanism. J Immunol (2001) 166:6855-6860.
83. Chatellier S, Kotb M: Preferential stimulation of human lymphocytes by oligodeoxynucleotides that copy DNA CpG motifs present in virulent genes of group A streptococci. Eur J Immunol (2000) 30:993-1001.
84. Filion MC, Filion B, Reader S, Menard S, Phillips NC: Modulation of interleukin-12 synthesis by DNA lacking the CpG motif and present in a mycobacterial cell wall complex. Cancer Immunol Immunother (2000) 49:325-334.
85. Sun S, Beard C, Jaenisch R, Jones P, Sprent J: Mitogenicity of DNA from different organisms for murine B cells. J Immunol (1997) 159:3119-3125.
86. Sun S, Kishimoto H, Sprent J: DNA as an adjuvant: Capacity of insect DNA and synthetic oligodeoxynucleotides to augment T cell responses to specific antigen. J Exp Med (1998) 187:1145-1150.
87. Wang Y, Wang W, Li N, Yu Y, Cao X: Activation of antigen-presenting cells by immunostimulatory plant DNA: A natural resource for potential adjuvant. Vaccine (2002) 20:2764-2771.
88. Ishii KJ, Suzuki K, Coban C, Takeshita F, Itoh Y, Matoba H, Kohn LD, Klinman DM: Genomic DNA released by dying cells induces the maturation of APCs. J Immunol (2001) 167:2602-2607.
89. Ballas ZK, Krieg AM, Warren T, Rasmussen W, Davis HL, Waldschmidt M, Weiner GJ: Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol (2001) 167:4878-4886.
90. Gursel M, Verthelyi D, Gursel I, Ishii KJ, Klinman DM: Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. J Leukocyte Biol (2002) 71:813-820. The different stimulatory activities of two classes of CpG ODN, the D (A) and K (B) classes, are reported.
91. Hartmann G, Weeratna RD, Ballas ZK, Payette P, Blackwell S, Suparto I, Rasmussen WL, Waldschmidt M, Sajuthi D, Purcell RH et al: Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J Immunol (2000) 164:1617-1624. This important report demonstrates that CpG ODNs can activate the immune system of primates.
92. Sester DP, Naik S, Beasley SJ, Hume DA, Stacey KJ: Phosphorothioate backbone modification modulates macrophage activation by CpG DNA. J Immunol (2000) 165:4165-4173.
93. Cho HJ, Takabayashi K, Cheng PM, Nguyen MD, Corr M, Tuck S, Raz E: Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nat Biotechnol (2000) 18:509-514.
94. McCluskie MJ, Weeratna RD, Payette PJ, Davis HL: The potential of CpG oligodeoxynucleotides as mucosal adjuvants. Crit Rev Immunol (2001) 21:103-120.
95. Jorgensen JB, Johansen A, Stenersen B, Sommer AI: CpG oligodeoxynucleotides and plasmid DNA stimulate Atlantic salmon (Salmo salar L) leucocytes to produce supernatants with antiviral activity. Dev Comp Immunol (2001) 25:313-321.
96. Kamstrup S, Verthelyi D, Klinman DM: Response of porcine peripheral blood mononuclear cells to CpG-containing oligodeoxynucleotides. Vet Microbiol (2001) 78:353-362.
97. Kanellos TS, Sylvester ID, Butler VL, Ambali AG, Partidos CD, Hamblin AS, Russell PH: Mammalian granulocyte-macrophage colony-stimulating factor and some CpG motifs have an effect on the immunogenicity of DNA and subunit vaccines in fish. Immunology (1999) 96:507-510.
98. Pontarollo RA, Rankin R, Babiuk LA, Godson DL, Griebel PJ, Hecker R, Krieg AM, van Drunen Littel-van den Hurk S: Monocytes are required for optimum in vitro stimulation of bovine peripheral blood mononuclear cells by non-methylated CpG motifs. Vet Immunol Immunopathol (2002) 84:43-59.
99. Rankin R, Pontarollo R, Ioannou X, Krieg AM, Hecker R, Babiuk LA, van Drunen Littel-van den Hurk S: CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. Antisense Nucleic Acid Drug Dev (2001) 11:333-340. This paper constitutes a good demonstration that CpG ODNs with motif 5′-GTCGTT (class B ODNs) can activate the immune cells of a variety of species.
100. Vleugels B, Ververken C, Goddeeris BM: Stimulatory effect of CpG sequences on humoral response in chickens. Poult Sci (2002) 81:1317-1321.
101. Vollmer J, Janosch A, Laucht M, Ballas ZK, Schetter C, Krieg AM: Highly immunostimulatory CpG-free oligodeoxynucleotides for activation of human leukocytes. Antisense Nucleic Acid Drug Dev (2002) 12:165-175.
102. Ballas ZK, Rasmussen WL, Krieg AM: Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J Immunol (1996) 157:1840-1845.
103. Krug A, Rothenfusser S, Hornung V, Jahrsdorfer B, Blackwell S, Ballas ZK, Endres S, Krieg AM, Hartmann G: Identification of CpG oligonucleotide sequences with high induction of IFN-α/β in plasmacytoid dendritic cells. Eur J Immunol (2001) 31:2154-2163. Characterization of chimeric A class ODNs, and a description of their immunostimulatory profile.
104. Park Y, Chang YS, Lee SW, Cho SY, Kim YK, Min KU, Kim YY, Cho SH, Sung YC: The enhanced effect of a hexameric deoxyriboguanosine run conjugation to CpG oligodeoxynucleotides on protection against allergic asthma. J Allergy Clin Immunol (2001) 108:570-576.
105. Prasad V, Hashim S, Mukhopadhyay A, Basu SK, Roy RP: Oligonucleotides tethered to a short polyguanylic acid stretch are targeted to macrophages: Enhanced antiviral activity of a vesicular stomatitis virus-specific antisense oligonucleotide. Antimicrob Agents Chemother (1999) 43:2689-2696.
106. Shen W, Waldschmidt M, Zhao X, Ratliff T, Krieg AM: Antitumor mechanisms of oligodeoxynucleotides with CpG and polyG motifs in murine prostate cancer cells: Decrease of NF-κB and AP-1 binding activities and induction of apoptosis. Antisense Nucleic Acid Drug Dev (2002) 12:155-164.
107. Chen Y, Lenert P, Weeratna R, McCluskie M, Wu T, Davis HL, Krieg AM: Identification of methylated CpG motifs as inhibitors of the immune stimulatory CpG motifs. Gene Ther (2001) 8:1024-1032.
108. Halpern MD, Pisetsky DS: In vitro inhibition of murine IFNγ production by phosphorothioate deoxyguanosine oligomers. Immunopharmacology (1995) 29:47-52.
109. Zhu FG, Reich CF, Pisetsky DS: Inhibition of murine macrophage nitric oxide production by synthetic oligonucleotides. J Leukocyte Biol (2002) 71:686-694.
110. Krieg AM, Wu T, Weeratna R, Efler SM, Love-Homan L, Yang L, Yi AK, Short D, Davis HL: Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc Natl Acad Sci USA (1998) 95:12631-12636. This paper is one of the first publications describing the inhibition of CpG ODN-mediated immune activation by inhibitory or suppressive ODN sequence motifs.
111. Lenert P, Stunz L, Yi AK, Krieg AM, Ashman RF: CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-κB activation. Antisense Nucleic Acid Drug Dev (2001) 11:247-256.
112. Stunz LL, Lenert P, Peckham D, Yi AK, Haxhinasto S, Chang M, Krieg AM, Ashman RF: Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells. Eur J Immunol (2002) 32:1212-1222.
113. Zhao H, Cheng SH, Yew NS: Requirements for effective inhibition of immunostimulatory CpG motifs by neutralizing motifs. Antisense Nucleic Acid Drug Dev (2000) 10:381-389.
114. Yamada H, Gursel I, Takeshita F, Conover J, Ishii KJ, Gursel M, Takeshita S, Klinman DM: Effect of suppressive DNA on CpG-induced immune activation. J Immunol (2002) 169:5590-5594.
115. Zeuner RA, Ishii KJ, Lizak MJ, Gursel I, Yamada H, Klinman DM, Verthelyi D: Reduction of CpG-induced arthritis by suppressive oligodeoxynucleotides. Arthritis Rheum (2002) 46:2219-2224.
116. Iyer RP, Roland A, Zhou W, Ghosh K: Modified oligonucleotides -Synthesis, properties and applications. Curr Opin Mol Ther (1999) 1:344-358. A comprehensive review on chemical modifications of ODNs.
117. Uhlmann E, Peyman A: Antisense oligonucleotides: A new therapeutic principle. Chem Rev (1990) 90:543-584.
118. Sester DP, Naik S, Beasley SJ, Hume DA, Stacey KJ: Phosphorothioate backbone modification modulates macrophage activation by CpG DNA. J Immunol (2000) 165:4165-4173.
119. Yu D, Kandimalla ER, Roskey A, Zhao Q, Chen L, Chen J, Agrawal S: Stereo-enriched phosphorothioate oligodeoxynucleotides: Synthesis, biophysical and biological properties. Bioorg Med Chem (2000) 8:275-284.
120. Yu D, Kandimalla ER, Zhao Q, Cong Y, Agrawal S: Immunostimulatory properties of phosphorothioate CpG DNA containing both 3′-5′- and 2′-5′-internucleotide linkages. Nucleic Acids Res (2002) 30:1613-1619.
121. Yu D, Kandimalla ER, Zhao Q, Cong Y, Agrawal S: Immunostimulatory activity of CpG oligonucleotides containing non-ionic methylphosphonate linkages. Bioorg Med Chem (2001) 9:2803-2808.
122. Kandimalla ER, Yu D, Zhao Q, Agrawal S: Effect of chemical modifications of cytosine and guanine in a CpG-motif of oligonucleotides: Structure-immunostimulatory activity relationships. Bioorg Med Chem (2001) 9:807-813.
123. Agrawal S, Kandimalla ER: Medicinal chemistry and therapeutic potential of CpG DNA. Trends Mol Med (2002) 8:114-121.
124. Henry S, Stecker K, Brooks D, Monteith D, Conklin B, Bennett CF: Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. J Pharmacol Exp Ther (2000) 292:468-479.
125. Yu D, Kandimalla ER, Zhao Q, Cong Y, Agrawal S: Modulation of immunostimulatory activity of CpG oligonucleotides by sitespecific deletion of nucleobases. Bioorg Med Chem Lett (2001) 11:2263-2267.
126. Yu D, Kandimalla ER, Cong Y, Tang J, Tang JY, Zhao Q, Agrawal S: Design, synthesis, and immunostimulatory properties of CpG DNAs containing alkyl-linker substitutions: Role of nucleosides in the flanking sequences. J Med Chem (2002) 45:4540-4548.
127. Krieg AM, Love-Homan L, Yi AK, Harty JT: CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J Immunol (1998) 161:2428-2434.
128. Zimmermann S, Egeter O, Hausmann S, Lipford GB, Rocken M, Wagner H, Heeg K: CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol (1998) 160:3627-3630.
129. Olbrich AR, Schimmer S, Heeg K, Schepers K, Schumacher TN, Dittmer U: Effective postexposure treatment of retrovirus-induced disease with immunostimulatory DNA containing CpG motifs. J Virol (2002) 76:11397-11404.
130. Davis HL: Use of CpG DNA for enhancing specific immune responses. Curr Top Microbiol Immunol (2000) 247:171-183.
131. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV: CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med(1997) 186:1623-1631.
132. Krieg AM: DNA-based immune enhancers. Curr Opin Drug Discovery Dev (2000) 3:214-221.
133. Davila E, Celis E: Repeated administration of cytosinephosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. J Immunol (2000) 165:539-547.
134. Verthelyi D, Kenney RT, Seder RA, Gam AA, Friedag B, Klinman DM: CpG oligodeoxynucleotides as vaccine adjuvants in primates. J Immunol (2002) 168:1659-1663.
135. Davis HL, Suparto II, Weeratna RR, Jumintarto, Iskandriati DD, Chamzah SS, Ma'ruf AA, Nente CC, Pawitri DD, Krieg AM et al: CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. Vaccine (2000) 18:1920-1924. An important report demonstrating that CpG ODNs have immunostimulatory activity in primates.
136. McCluskie MJ, Weeratna RD, Payette PJ, Davis HL: The use of CpG DNA as a mucosal vaccine adjuvant. Curr Opin Invest Drugs (2001) 2:35-39. An excellent review on the use of CpG ODNs as vaccine adjuvants.
137. McCluskie MJ, Davis HL: CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice. J Immunol (1998) 161:4463-4466.
138. Carpentier AF, Xie J, Mokhtari K, Delattre JY: Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin Cancer Res (2000) 6:2469-2473.
139. Weiner GJ, Liu HM, Wooldridge JE, Dahle CE, Krieg AM: Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci USA (1997) 94:10833-10837.
140. Wooldridge JE, Ballas Z, Krieg AM, Weiner GJ: Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood (1997) 89:2994-2998.
141. Kline JN: Effects of CpG DNA on Th1/Th2 balance in asthma. Curr Top Microbiol Immunol (2000) 247:211-225. An excellent review on the use of CpG ODNs in the treatment of asthma.
142. Kline JN, Waldschmidt TJ, Businga TR, Lemish JE, Weinstock JV, Thorne PS, Krieg AM: Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. J Immunol (1998) 160:2555-2559.
143. Broide D, Schwarze J, Tighe H, Gifford T, Nguyen MD, Malek S, Van Uden J, Martin-Orozco E, Gelfand EW, Raz E: Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice. J Immunol (1998) 161:7054-7062.
144. Kitagaki K, Jain VV, Businga TR, Hussain I, Kline JN: Immunomodulatory effects of CpG oligodeoxynucleotides on established Th2 responses. Clin Diagn Lab Immunol (2002) 9:1260-1269.
145. Jahrsdorfer B, Jox R, Muhlenhoff L, Tschoep K, Krug A, Rothenfusser S, Meinhardt G, Emmerich B, Endres S, Hartmann G: Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN. J Leukocyte Biol (2002) 72:83-92.
146. Zhang Z: Technology evaluation: EPI-2010, EpiGenesis. Curr Opin Mol Ther (2002) 3:275-280.